Literature DB >> 16261198

[Preventive and therapeutic effects of recombinant IFN-alpha2b nasal spray on SARS-CoV infection in Macaca mulata].

Hong Gao1, Li-lan Zhang, Qiang Wei, Zhao-jun Duan, Xin-ming Tu, Zhi-ai Yu, Wei Deng, Li-ping Zhang, Lin-lin Bao, Bin Zhang, Wei Tong, Yun-de Hou, Bing-lin Zhang, Lan Huang, Chuan Qin.   

Abstract

OBJECTIVE: To study the preventive and therapeutic effects of recombinant IFN-alpha2b for nasal spray on SARS-CoV infection in Macaca mulata (rhesus monkey).
METHODS: Ten rhesus monkeys were divided into two groups, 5 in interferon group, and 5 in control group. Before and after SARS-CoV attack, the virus was detected in samples such as pharyngeal swab in all the two groups by Real-time PCR (RT-PCR) and virus isolation was performed.
RESULTS: After virus attack, the level of SARS-CoV-specific IgG and neutralizing antibody were induced by SARS-CoV in the interferon group was weaker than in control group. Hematology items showed no apparent changes after virus attack in treated group. Through pathological examination, the morphology of the lung tissues of two Macaques in the treated group was normal, while the other three displayed the interstitial pneumonia with the thickened septum and infiltration with mononuclear cells. Among which, one monkey showed part of thickened septum fused with each other. These lesions in the interferon treated animals were similar to those seen in the animals in control group, but with smaller scope of pathological changes. No significant abnormity was detected in other organs.
CONCLUSION: Recombinant IFN-alpha2b could effectively interdict or weaken SARS-CoV injury in monkeys.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261198

Source DB:  PubMed          Journal:  Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi        ISSN: 1003-9279


  6 in total

1.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.

Authors:  Dale L Barnard; Yohichi Kumaki
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

2.  A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits.

Authors:  Lulu Gao; Shouyi Yu; Qing Chen; Zhaojun Duan; Jie Zhou; Chen Mao; Dexian Yu; Wenchang Zhu; Jun Nie; Yunde Hou
Journal:  Vaccine       Date:  2010-04-13       Impact factor: 3.641

Review 3.  Drug Discovery Strategies for SARS-CoV-2.

Authors:  Zeenat A Shyr; Kirill Gorshkov; Catherine Z Chen; Wei Zheng
Journal:  J Pharmacol Exp Ther       Date:  2020-07-28       Impact factor: 4.030

Review 4.  Severe Acute Respiratory Syndrome Coronavirus 2: The Role of the Main Components of the Innate Immune System.

Authors:  Akbar Anaeigoudari; Hamid Reza Mollaei; Mohammad Kazemi Arababadi; Reza Nosratabadi
Journal:  Inflammation       Date:  2021-09-15       Impact factor: 4.657

Review 5.  Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue.

Authors:  Kun-Ling Shen; Yong-Hong Yang
Journal:  World J Pediatr       Date:  2020-02-05       Impact factor: 9.186

Review 6.  Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.

Authors:  Kunling Shen; Yonghong Yang; Tianyou Wang; Dongchi Zhao; Yi Jiang; Runming Jin; Yuejie Zheng; Baoping Xu; Zhengde Xie; Likai Lin; Yunxiao Shang; Xiaoxia Lu; Sainan Shu; Yan Bai; Jikui Deng; Min Lu; Leping Ye; Xuefeng Wang; Yongyan Wang; Liwei Gao
Journal:  World J Pediatr       Date:  2020-02-07       Impact factor: 9.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.